Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pleural Neoplasms | 24 | 2022 | 607 | 5.070 |
Why?
|
Mesothelioma | 23 | 2022 | 818 | 4.660 |
Why?
|
Lung Neoplasms | 37 | 2023 | 13104 | 2.180 |
Why?
|
Solitary Pulmonary Nodule | 6 | 2020 | 266 | 1.360 |
Why?
|
Mediastinal Neoplasms | 4 | 2022 | 423 | 1.270 |
Why?
|
Pneumonectomy | 13 | 2021 | 1094 | 1.250 |
Why?
|
Pleural Diseases | 3 | 2015 | 139 | 1.210 |
Why?
|
Thoracic Surgery, Video-Assisted | 2 | 2020 | 273 | 1.020 |
Why?
|
Lung Diseases, Interstitial | 7 | 2024 | 808 | 0.810 |
Why?
|
Tomography, X-Ray Computed | 30 | 2024 | 20130 | 0.770 |
Why?
|
Neoplasm Staging | 19 | 2023 | 11031 | 0.770 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 9 | 2023 | 5223 | 0.730 |
Why?
|
Diagnostic Imaging | 7 | 2019 | 3508 | 0.700 |
Why?
|
Multiple Pulmonary Nodules | 3 | 2020 | 153 | 0.700 |
Why?
|
Bronchoscopy | 3 | 2022 | 862 | 0.650 |
Why?
|
Anesthesia, General | 3 | 2022 | 1171 | 0.600 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2016 | 450 | 0.520 |
Why?
|
Benchmarking | 1 | 2021 | 1042 | 0.490 |
Why?
|
Arthritis, Rheumatoid | 7 | 2024 | 3712 | 0.490 |
Why?
|
Bronchial Fistula | 1 | 2013 | 85 | 0.450 |
Why?
|
Thoracic Neoplasms | 3 | 2019 | 268 | 0.410 |
Why?
|
Radiology | 5 | 2024 | 2099 | 0.400 |
Why?
|
Magnetic Resonance Imaging | 10 | 2021 | 35425 | 0.370 |
Why?
|
Unnecessary Procedures | 1 | 2013 | 432 | 0.360 |
Why?
|
Tumor Burden | 6 | 2020 | 1915 | 0.340 |
Why?
|
Surgery, Computer-Assisted | 2 | 2015 | 1018 | 0.340 |
Why?
|
Bronchiectasis | 2 | 2022 | 128 | 0.320 |
Why?
|
Anesthesia | 1 | 2018 | 1561 | 0.300 |
Why?
|
Myxoma | 1 | 2008 | 130 | 0.290 |
Why?
|
Diffusion Magnetic Resonance Imaging | 4 | 2015 | 2737 | 0.280 |
Why?
|
Humans | 89 | 2024 | 744366 | 0.280 |
Why?
|
Primary Prevention | 1 | 2013 | 1167 | 0.270 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 3086 | 0.260 |
Why?
|
Airway Obstruction | 2 | 2022 | 664 | 0.250 |
Why?
|
Heart Neoplasms | 1 | 2008 | 374 | 0.240 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7282 | 0.240 |
Why?
|
Aged, 80 and over | 19 | 2021 | 57776 | 0.240 |
Why?
|
Aged | 38 | 2022 | 163288 | 0.240 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2019 | 288 | 0.240 |
Why?
|
Clinical Trials as Topic | 2 | 2019 | 7914 | 0.230 |
Why?
|
Lung Transplantation | 2 | 2012 | 1155 | 0.230 |
Why?
|
Pulmonary Artery | 4 | 2014 | 1912 | 0.230 |
Why?
|
Positron-Emission Tomography | 8 | 2022 | 6234 | 0.230 |
Why?
|
Middle Aged | 44 | 2022 | 213390 | 0.220 |
Why?
|
Internship and Residency | 1 | 2023 | 5791 | 0.220 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4034 | 0.210 |
Why?
|
Contrast Media | 8 | 2024 | 5300 | 0.210 |
Why?
|
Hyperthermia, Induced | 2 | 2018 | 403 | 0.210 |
Why?
|
Pneumothorax | 2 | 2020 | 379 | 0.210 |
Why?
|
Public Opinion | 2 | 2022 | 477 | 0.190 |
Why?
|
Lung | 8 | 2022 | 9857 | 0.190 |
Why?
|
Pulmonary Embolism | 5 | 2014 | 2375 | 0.190 |
Why?
|
Angiography | 3 | 2011 | 1639 | 0.190 |
Why?
|
Male | 47 | 2022 | 350115 | 0.190 |
Why?
|
Lymphatic Metastasis | 3 | 2021 | 2924 | 0.180 |
Why?
|
Intraoperative Care | 2 | 2015 | 767 | 0.180 |
Why?
|
Atrial Appendage | 1 | 2024 | 283 | 0.180 |
Why?
|
Neoplasm Invasiveness | 4 | 2020 | 3616 | 0.180 |
Why?
|
Postoperative Complications | 2 | 2015 | 15297 | 0.180 |
Why?
|
Retrospective Studies | 22 | 2022 | 77460 | 0.180 |
Why?
|
Female | 49 | 2022 | 380193 | 0.170 |
Why?
|
Emphysema | 1 | 2022 | 247 | 0.170 |
Why?
|
Iohexol | 2 | 2012 | 196 | 0.170 |
Why?
|
Cisplatin | 2 | 2018 | 1662 | 0.170 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2020 | 323 | 0.160 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2012 | 3326 | 0.160 |
Why?
|
Adult | 31 | 2022 | 214052 | 0.160 |
Why?
|
Motion | 2 | 2020 | 798 | 0.160 |
Why?
|
Mass Screening | 1 | 2013 | 5253 | 0.150 |
Why?
|
Students, Medical | 2 | 2021 | 1862 | 0.150 |
Why?
|
Dermatitis | 1 | 2019 | 199 | 0.150 |
Why?
|
Sensitivity and Specificity | 9 | 2020 | 14723 | 0.150 |
Why?
|
Education, Distance | 1 | 2021 | 251 | 0.150 |
Why?
|
Reference Standards | 1 | 2021 | 1025 | 0.150 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2020 | 629 | 0.150 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2022 | 451 | 0.140 |
Why?
|
Pulmonary Emphysema | 4 | 2016 | 672 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2023 | 9240 | 0.140 |
Why?
|
Expert Testimony | 1 | 2019 | 356 | 0.140 |
Why?
|
Prognosis | 9 | 2021 | 29060 | 0.140 |
Why?
|
Follow-Up Studies | 6 | 2023 | 39052 | 0.130 |
Why?
|
Biopsy | 2 | 2022 | 6755 | 0.130 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2020 | 721 | 0.130 |
Why?
|
Survival Rate | 6 | 2021 | 12788 | 0.130 |
Why?
|
Respiration | 2 | 2020 | 1653 | 0.130 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2019 | 388 | 0.120 |
Why?
|
Clinical Clerkship | 1 | 2020 | 532 | 0.120 |
Why?
|
Neoplasms | 2 | 2021 | 21696 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 890 | 0.120 |
Why?
|
Cardiac Tamponade | 1 | 2005 | 173 | 0.120 |
Why?
|
Positive-Pressure Respiration | 1 | 2018 | 633 | 0.120 |
Why?
|
Deoxycytidine | 1 | 2018 | 826 | 0.120 |
Why?
|
Ductus Arteriosus, Patent | 1 | 2005 | 209 | 0.110 |
Why?
|
Perfusion Imaging | 1 | 2015 | 195 | 0.110 |
Why?
|
Combined Modality Therapy | 5 | 2018 | 8642 | 0.110 |
Why?
|
Consensus | 2 | 2019 | 2960 | 0.110 |
Why?
|
Pleurisy | 1 | 2013 | 53 | 0.110 |
Why?
|
Algorithms | 3 | 2021 | 13882 | 0.110 |
Why?
|
Bronchi | 1 | 2016 | 840 | 0.110 |
Why?
|
Neoadjuvant Therapy | 2 | 2015 | 2727 | 0.110 |
Why?
|
Lung Volume Measurements | 1 | 2013 | 378 | 0.110 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2017 | 719 | 0.110 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2018 | 2649 | 0.100 |
Why?
|
Radiotherapy | 1 | 2019 | 1533 | 0.100 |
Why?
|
Carcinoma in Situ | 1 | 2017 | 806 | 0.100 |
Why?
|
Pandemics | 2 | 2023 | 8385 | 0.100 |
Why?
|
Artifacts | 1 | 2020 | 1904 | 0.100 |
Why?
|
Registries | 3 | 2018 | 8091 | 0.100 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1692 | 0.100 |
Why?
|
Adenocarcinoma | 2 | 2019 | 6364 | 0.100 |
Why?
|
Image Enhancement | 3 | 2012 | 2921 | 0.090 |
Why?
|
Radiography, Thoracic | 3 | 2020 | 1265 | 0.090 |
Why?
|
Mycobacterium | 1 | 2012 | 249 | 0.090 |
Why?
|
Bronchopulmonary Sequestration | 1 | 2010 | 42 | 0.090 |
Why?
|
Logistic Models | 4 | 2022 | 13409 | 0.090 |
Why?
|
Radiography, Interventional | 2 | 2015 | 1095 | 0.090 |
Why?
|
Prospective Studies | 6 | 2022 | 53290 | 0.090 |
Why?
|
Reproducibility of Results | 10 | 2014 | 19905 | 0.090 |
Why?
|
Radionuclide Imaging | 1 | 2013 | 2031 | 0.090 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 3 | 2016 | 3047 | 0.090 |
Why?
|
Young Adult | 7 | 2018 | 56429 | 0.090 |
Why?
|
Incidental Findings | 1 | 2014 | 689 | 0.090 |
Why?
|
Predictive Value of Tests | 4 | 2015 | 15078 | 0.090 |
Why?
|
Asbestos | 1 | 2011 | 251 | 0.080 |
Why?
|
Body Burden | 1 | 2009 | 158 | 0.080 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2417 | 0.080 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 12356 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2043 | 0.080 |
Why?
|
Gadolinium DTPA | 1 | 2012 | 836 | 0.080 |
Why?
|
Radiation Dosage | 2 | 2014 | 1928 | 0.080 |
Why?
|
Iodine | 1 | 2010 | 286 | 0.080 |
Why?
|
Pleural Effusion, Malignant | 1 | 2009 | 101 | 0.080 |
Why?
|
Tracheal Diseases | 1 | 2008 | 113 | 0.080 |
Why?
|
Mesentery | 1 | 2008 | 205 | 0.080 |
Why?
|
Pulmonary Valve Stenosis | 1 | 2008 | 183 | 0.080 |
Why?
|
Bronchial Diseases | 1 | 2008 | 151 | 0.080 |
Why?
|
Fibromatosis, Aggressive | 1 | 2008 | 118 | 0.080 |
Why?
|
Immune Tolerance | 1 | 2016 | 2259 | 0.070 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2009 | 314 | 0.070 |
Why?
|
Heart Defects, Congenital | 1 | 2024 | 4583 | 0.070 |
Why?
|
Palliative Care | 3 | 2021 | 3493 | 0.070 |
Why?
|
Cohort Studies | 6 | 2021 | 40559 | 0.070 |
Why?
|
Phlebography | 1 | 2008 | 333 | 0.070 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15535 | 0.070 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 13693 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2018 | 11366 | 0.070 |
Why?
|
Feasibility Studies | 1 | 2016 | 5077 | 0.070 |
Why?
|
Aneurysm, False | 1 | 2008 | 276 | 0.070 |
Why?
|
Flow Cytometry | 1 | 2016 | 5974 | 0.070 |
Why?
|
Treatment Outcome | 8 | 2021 | 63107 | 0.070 |
Why?
|
Radiation Protection | 1 | 2009 | 419 | 0.070 |
Why?
|
Radiography | 2 | 2013 | 7023 | 0.070 |
Why?
|
Proteoglycans | 1 | 2009 | 837 | 0.070 |
Why?
|
Radiographic Image Enhancement | 1 | 2010 | 885 | 0.060 |
Why?
|
Dyspnea | 1 | 2013 | 1303 | 0.060 |
Why?
|
Risk Factors | 9 | 2022 | 72296 | 0.060 |
Why?
|
Thoracic Surgical Procedures | 1 | 2009 | 342 | 0.060 |
Why?
|
Pulmonary Medicine | 1 | 2007 | 213 | 0.060 |
Why?
|
Respiratory Tract Infections | 1 | 2012 | 961 | 0.060 |
Why?
|
Smoking | 2 | 2024 | 8987 | 0.060 |
Why?
|
Electronic Health Records | 1 | 2021 | 4468 | 0.060 |
Why?
|
Breast Diseases | 1 | 2007 | 443 | 0.060 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3590 | 0.060 |
Why?
|
Biopsy, Needle | 1 | 2009 | 1641 | 0.060 |
Why?
|
Reoperation | 1 | 2013 | 4201 | 0.060 |
Why?
|
Pelvis | 1 | 2008 | 730 | 0.060 |
Why?
|
Software | 1 | 2017 | 4441 | 0.060 |
Why?
|
Genetic Linkage | 1 | 2009 | 2421 | 0.060 |
Why?
|
Survival Analysis | 2 | 2016 | 10252 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2014 | 3476 | 0.050 |
Why?
|
Surgical Wound Infection | 1 | 2012 | 1540 | 0.050 |
Why?
|
United States | 4 | 2019 | 69872 | 0.050 |
Why?
|
Lung Diseases | 1 | 2013 | 1887 | 0.050 |
Why?
|
Genomics | 1 | 2018 | 5717 | 0.050 |
Why?
|
Decision Support Systems, Clinical | 1 | 2011 | 1164 | 0.050 |
Why?
|
Peritoneal Neoplasms | 1 | 2008 | 665 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
Sarcoidosis | 1 | 2007 | 506 | 0.050 |
Why?
|
Mucin-5B | 1 | 2022 | 141 | 0.050 |
Why?
|
Regression Analysis | 1 | 2012 | 6459 | 0.050 |
Why?
|
Ethanol | 1 | 2008 | 1342 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2012 | 2265 | 0.050 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 1184 | 0.050 |
Why?
|
Thrombosis | 1 | 2005 | 2968 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 11525 | 0.050 |
Why?
|
Gene Expression | 1 | 2014 | 7798 | 0.050 |
Why?
|
Observer Variation | 3 | 2014 | 2593 | 0.050 |
Why?
|
Risk Assessment | 3 | 2012 | 23336 | 0.050 |
Why?
|
Biopsy, Fine-Needle | 2 | 2016 | 1094 | 0.040 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 2016 | 0.040 |
Why?
|
Emergency Medical Services | 1 | 2011 | 1917 | 0.040 |
Why?
|
Case-Control Studies | 4 | 2022 | 21748 | 0.040 |
Why?
|
Vital Capacity | 2 | 2016 | 925 | 0.040 |
Why?
|
Lower Extremity | 1 | 2008 | 1158 | 0.040 |
Why?
|
Life Style | 2 | 2022 | 3835 | 0.040 |
Why?
|
X-Rays | 1 | 2020 | 301 | 0.040 |
Why?
|
Diagnosis, Differential | 4 | 2020 | 12961 | 0.040 |
Why?
|
Foundations | 1 | 2019 | 94 | 0.040 |
Why?
|
Gadolinium | 1 | 2024 | 952 | 0.040 |
Why?
|
Artificial Intelligence | 2 | 2024 | 2213 | 0.040 |
Why?
|
Indocyanine Green | 1 | 2020 | 239 | 0.040 |
Why?
|
Disease Progression | 3 | 2022 | 13286 | 0.040 |
Why?
|
Soft Tissue Neoplasms | 1 | 2008 | 1363 | 0.040 |
Why?
|
Radiopharmaceuticals | 1 | 2009 | 2645 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2016 | 10183 | 0.040 |
Why?
|
International Agencies | 1 | 2019 | 240 | 0.040 |
Why?
|
Venous Thrombosis | 1 | 2008 | 1239 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2020 | 6896 | 0.040 |
Why?
|
Coloring Agents | 1 | 2020 | 566 | 0.040 |
Why?
|
Telomere | 1 | 2024 | 910 | 0.040 |
Why?
|
Forced Expiratory Volume | 2 | 2016 | 1745 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9445 | 0.040 |
Why?
|
Curriculum | 2 | 2021 | 3605 | 0.040 |
Why?
|
Hematologic Neoplasms | 1 | 2009 | 1832 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6539 | 0.040 |
Why?
|
Bronchial Arteries | 1 | 2016 | 20 | 0.040 |
Why?
|
Demography | 1 | 2022 | 1655 | 0.040 |
Why?
|
Total Lung Capacity | 1 | 2016 | 143 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2019 | 449 | 0.040 |
Why?
|
Adolescent | 4 | 2018 | 85779 | 0.030 |
Why?
|
Graft vs Host Disease | 1 | 2008 | 2958 | 0.030 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2021 | 740 | 0.030 |
Why?
|
Catheter Ablation | 1 | 2008 | 2758 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2011 | 8949 | 0.030 |
Why?
|
Remission Induction | 1 | 2019 | 2385 | 0.030 |
Why?
|
Autoantibodies | 1 | 2022 | 2036 | 0.030 |
Why?
|
Pain | 1 | 2008 | 4988 | 0.030 |
Why?
|
Mediastinum | 1 | 2014 | 267 | 0.030 |
Why?
|
Methotrexate | 1 | 2019 | 1728 | 0.030 |
Why?
|
Mycobacterium avium Complex | 1 | 2012 | 60 | 0.030 |
Why?
|
Area Under Curve | 1 | 2016 | 1655 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4933 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2022 | 5867 | 0.020 |
Why?
|
Boston | 2 | 2015 | 9312 | 0.020 |
Why?
|
Precancerous Conditions | 1 | 2017 | 975 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2005 | 1851 | 0.020 |
Why?
|
Time Factors | 3 | 2020 | 40075 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2021 | 4851 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2009 | 17446 | 0.020 |
Why?
|
Odds Ratio | 1 | 2022 | 9849 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2008 | 5445 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2108 | 0.020 |
Why?
|
Prevalence | 3 | 2012 | 15221 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2019 | 1338 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2015 | 1771 | 0.020 |
Why?
|
Proteomics | 1 | 2022 | 3638 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2019 | 2850 | 0.020 |
Why?
|
Fibromatosis, Abdominal | 1 | 2008 | 24 | 0.020 |
Why?
|
Computer Graphics | 1 | 2011 | 361 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2618 | 0.020 |
Why?
|
ROC Curve | 1 | 2016 | 3528 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2013 | 1617 | 0.020 |
Why?
|
Diaphragm | 1 | 2010 | 349 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2021 | 2530 | 0.020 |
Why?
|
Comorbidity | 2 | 2016 | 10388 | 0.020 |
Why?
|
Lod Score | 1 | 2009 | 614 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2015 | 2879 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 4446 | 0.020 |
Why?
|
Incidence | 2 | 2019 | 20952 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 3508 | 0.020 |
Why?
|
Massachusetts | 2 | 2011 | 8662 | 0.020 |
Why?
|
Vinblastine | 1 | 2008 | 502 | 0.020 |
Why?
|
Syndrome | 1 | 2013 | 3252 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2015 | 3480 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4751 | 0.020 |
Why?
|
Spirometry | 1 | 2009 | 865 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2021 | 4253 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2014 | 3921 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2011 | 1431 | 0.010 |
Why?
|
Siblings | 1 | 2007 | 854 | 0.010 |
Why?
|
Kinetics | 1 | 2011 | 6476 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 2008 | 847 | 0.010 |
Why?
|
Doxorubicin | 1 | 2008 | 2234 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 7730 | 0.010 |
Why?
|
Pedigree | 1 | 2009 | 4642 | 0.010 |
Why?
|
Genetic Testing | 1 | 2014 | 3444 | 0.010 |
Why?
|
Phenotype | 2 | 2009 | 16367 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12244 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2007 | 20824 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2021 | 8861 | 0.010 |
Why?
|
Pain Measurement | 1 | 2008 | 3420 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6194 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2007 | 2638 | 0.010 |
Why?
|
Models, Biological | 1 | 2012 | 9584 | 0.010 |
Why?
|
Animals | 2 | 2015 | 168768 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2009 | 15520 | 0.010 |
Why?
|
Mice | 1 | 2009 | 81201 | 0.000 |
Why?
|